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Low doses of environmental allergens have been proposed to increase bronchial hyperreactivity in sensitised 
individuals, without causing immediate asthmatic reactions. The primary aim of the present study was to evaluate 
whether repeated low doses of allergen, that do not cause overt bronchoconstriction, cause augmented non-specific 
bronchial reactivity. A secondary aim was to evaluate whether any changes in reactivity are associated with 
increased variability of lung function, and whether signs of inflammatory activity could be found. To do this, mild 
asthmatic patients without regular symptoms, but with both immediate and late reactions in response to a high dose 
of inhaled cat allergen extract, were included in a double blind, placebo controlled, cross-over study in which a low 
dose of allergen was administered on four consecutive days (Monday to Thursday). The dose of allergen was 
individualised for each patient, and was calculated to be 25% of the total dose given to produce an immediate and 
late response at screening. Repeated low dose allergen exposure produced a significant increase in methacholine 
reactivity compared to placebo, whereas FEV, in the morning did not significantly change during the allergen week. 
Each low dose allergen exposure caused small changes in FEV, (approximately 7% drop), which was significant vs. 
placebo only on day 2 (Tuesday). During the allergen week, six of eight patients reported asthma symptoms on at 
least one occasion, and variability in lung function, measured with a portable spirometer, was increased. Repeated 
low doses of allergen also produced a significant increase of P-ECP vs. placebo, without a significant rise in 
circulating eosinophils. However, no significant changes in circulating CD3, CD4, CD8, CD19, or CD25 cells were 
found, evaluated by FACS analysis. We conclude that low doses of allergen produce signs of a mild exacerbation of 
asthma, including increased bronchial reactivity to methacholine. This clinical model may be useful to evaluate both 
the pathophysiological mechanisms of asthma, and the effects of novel anti-asthma drugs. 
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Introduction 
Two fundamental features of asthma are variability of 
airway calibre and increased bronchial hyperreactivity to 
non-specific stimuli (BHR)( 1). The degree of BHR has been 
related to the number of inflammatory cells in the blood 
and airways, suggesting that the physiological dysfunctions 
in asthma are caused by an underlying inflammatory pro- 
cess (2-8). This is further supported in more recent studies, 
showing that the activation state of the inflammatory cells, 
especially eosinophils, is related to the degree of bronchial 
hyperreactivity and to the severity of asthma (9-15). 
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Allergens are considered to be important inducers of 
BHR in allergic asthmatic patients (6). Following high-dose 
allergen exposure in an allergic patient, an early asthmatic 
reaction (EAR) occurs immediately after exposure, and 
after 3-7 h a late asthmatic reaction (LAR) may develop in 
some patients (16,17). The EAR is transient, often resolving 
spontaneously within 1 h. The LAR, on the other hand, is 
associated with influx of inflammatory cells into the blood 
and airways, as well as the increase of BHR, which some- 
times can persist for several days (3,18-21). This high dose 
provocation model is often used to study pathophysio- 
logical mechanisms of allergic reactions, and to evaluate the 
effects of novel therapeutic agents developed for asthma 
(22). However, the model has also been criticised for being 
too experimental. 
A more common way to be exposed to an allergen may 
be repeated or chronic exposures to low doses. For 
example, exposure to house dust mite may occur mainly 
when sleeping, and exposure to low doses of animal dander 
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TABLE 1. Patient characteristics 
Pat. # 
1 
2 
3 
4 
5 
6 
I 
8 
Mean 
Sex 
M 
F 
F 
F 
F 
M 
F 
M 
Age FEV, 
(years) (% pred) 
21 88 
32 96 
36 112 
46 71 
22 87 
35 97 
26 104 
26 95 
31.2 93.8 
SPT RAST PD20 allergen 
(skin prick test) (class) (SQ) 
++++ 4 120 
++ 3 40 
++++ 3 6 
+++ 3 10 
++++ 3 250 
++++ 3 2100 
+++ 3 50 
+++ 3 400 
FEV, = Forced expiratory volume in 1 s. 
SPT = Skin prick test. 
SQ = standard quality units. 
may occur in many public areas (23,24). It has earlier been defined as a fall in FEV, of at least 20 and 15% from 
suggested that experimental exposures to repeated low baseline respectively. No overt allergen exposure or signifi- 
doses of allergen can increase BHR. These studies have cant respiratory infection was allowed to be present within 
however been unable to show any evidence of inflammatory four weeks prior to the study, or during the study. Three 
changes (25,26), and the doses of allergen used were not patients had evidence of concomitant allergy to pollen, but 
individualised. were studied outside of the pollen season. 
The aim of the present study was to develop a clinical 
experimental model of asthma, induced by lower doses of 
allergen than those causing an early and a late response. To 
do this, we gave patients with mild asthma either repeated 
inhalations of placebo, or four exposures of 25% of the 
individual dose of allergen known to cause an early and late 
response. We further asked whether this protocol would 
induce a mild exacerbation of asthma. To answer this, we 
measured bronchial methacholine reactivity, the daily 
variability in lung function, and the activation state of 
eosinophils (lo-12,15-21). 
STUDY DESIGN 
Screening 
Patients and methods 
The study was approved by the Ethics Committee in 
Giiteborg. Nine atopic patients mean age 31 years (range 
2046), with a history of asthma when exposed to cat, were 
included in the study, but one patient was excluded due 
to repeated accidental and symptomatic cat exposures. 
Characteristics of analysed patients are presented in 
Table 1. Skin prick test (SPT) and RAST were all positive 
to cat. SPT was graded in a plus system according to 
Northern standardisation, with histamine hydrochloride 
lOmgml-’ as the positive reference (27). RAST was 
analysed as CAP-RAST (Pharmacia, Uppsala, Sweden). 
All patients had mild asthma with mean FEV, 93% pre- 
dicted (71-112%; Table l), and did not require regular 
asthma therapy, although inhaled beta-2 agonists when 
needed was allowed at inclusion. At a screening day, high 
dose bronchial allergen challenge to cat allergen extract was 
performed. All patients included in the low-dose study 
presented both EAR and LAR at screening, which was 
The study started with a screening day when history, a skin 
prick test and a high dose bronchial allergen challenge 
screening was performed. The allergen dose causing EAR 
was determined (FEV, decreased at least 20% from 
baseline, within 10 min from the allergen dose), and the 
presence of LAR was confirmed (FEV, decreased at 
least 15% 3-7 h after the last allergen dose). At the end of 
the screening day (at 7 h), all patients received 30 mg 
prednisolone as a single dose, to attenuate any prolonged 
inflammatory processes. Sixteen patients were screened, but 
seven of these presented no late response. The logarithmic 
allergen doses were plotted against the fall in FEV, and 
PD20 values for each patient was calculated from the 
cumulative doses by linear interpolation on the log-linear 
curve. 
Repeated Low-dose Protocol 
In a double-blind cross over design, the patients were at 
least 10 days after screening randomised to daily bronchial 
exposure to low-dose allergen (cat) or placebo for 4 days. 
‘Low-dose’ was defined as 25% of the cumulative allergen 
PD20 on the screening day. The two periods of low-dose 
allergen or placebo inhalations, were separated by at least 
10 days. On the Monday, (before the first allergen/placebo 
exposure), and on the Friday, approximately 24 h after the 
last allergen/placebo exposure, a bronchial methacholine 
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FIG. 1. (a) Protocol of the repeated individualised low 
dose allergen exposure. The study is double blind, placebo 
controlled and of a cross over design. (b) Protocol of 
measurements during the allergen/placebo exposure 
weeks. The individualised low dose allergen inhalation or 
placebo inhalation were given 1 h after the end of the 
methacholine challenge on the Monday. Subsequent low 
dose allergen or placebo inhalations were given on 
Tuesday, Wednesday and Thursday mornings, and the 
last methacholine challenge was performed approximately 
24 h after the last inhalation of allergen/placebo. 
challenge was performed. The single dose of an oral gluco- 
corticoid (prednisone 30 mg) was given after the end of each 
treatment period. Blood samples for leucocyte-differential 
count were collected daily, and samples for ECP (eosinophil 
cationic protein, CAP, Pharmacia) were collected on 
Monday, Wednesday and Friday. 
After the daily low-dose allergen/placebo exposure 
(Monday to Thursday), the patients used a home- 
spirometer (Spirobank, MIR) to register FEV, and 
symptoms every second hour on five occasions during the 
rest of the day. 
BRONCHIAL CHALLENGE AND LUNG 
FUNCTION 
NebulisedDosimeteu 
The dosimeter ME.FAR MB3 (Brescia, Italy) was used 
for all bronchial challenges. The patient inhaled the dose 
of aerosol slowly by means of an inspiratory capacity 
breath, followed by 5 s of breath holding. The particle size 
of the aerosol is 0.55,~rn, when driven at the used air 
pressure of 1.65 kg cm ~ 2 and an air flow rate of 
70-75 1 min ~ ‘. The nebulisation time was set to one 
second which was selected to obtain an output of 10~1 
per breath. For each dose of methacholine or allergen, 
five inhalations were given. All bronchial challenges 
started with registration of basal FEV, (two measure- 
ments with at least 1 min between). If the measured FEV, 
was more than 65% predicted, the provocation was 
pursued with inhalation of diluent. 
High Dose Allergen Screening 
Allergen extract (cat) was purchased from the Allergologi- 
cal Laboratories (ALK), Copenhagen, Denmark. The 
‘high-dose’ allergen challenge on the screening day started 
with inhalation of the extract vehicle. FEV, was measured 
after 4 and 5 min, and the best FEV, of these was used as 
the baseline value. The allergen provocation protocol was 
started with 32 standardised quality units (SQ), nebulised 
for 1 s (five times). The allergen doses were given at 
two-fold increasing doses. However, if FEV, dropped less 
than 5% vs. baseline, the next four-fold increasing dose of 
allergen was given. FEV, was measured after at 5 and 
10 min (the best FEV, of two manoeuvres with 1 min 
between). The lowest FEV, at these respective time-points 
was regarded as the reaction to the given dose. The allergen 
provocation was stopped when FEV, had fallen >20% 
from baseline value, defined as the early asthmatic reaction 
(EAR). FEV, was then further measured after 15, 20, 30,45 
and 60 min (two FEV,-manoeuvres at every time point with 
1 min between). Hourly measures of FEV, was then made 
up to 7 h after EAR. An inhaled beta-2 agonist (Terbuta- 
line or Salbutamol) and a single oral dose of 30 mg 
prednisolone was given to reverse the LAR. 
Low Dose Allergen Challenge 
The dose of allergen given to each patient, was calculated 
to be 25% of the cumulative dose causing and early and 
late reaction. Briefly, the concentration of allergen extract 
causing the early and late reaction was dissolved 1:4 in 
saline. This individualised concentration of allergen extract, 
or the vehicle (placebo), was given to each patient in the 
morning from Monday to Friday during the randomised 
weeks. FEV, was followed for 1 h after each low-dose 
allergen provocation (measured at 5, 10, 20, 30, 45 and 
60 min after allergen). Prednisolone at a single dose of 
30 mg was given after methacholine challenge on Friday, to 
end each allergen/vehicle period. 
Methacholine Provocation Tests 
Methacholine challenge tests were performed on the 
Monday, before the first allergen/placebo dose, and on 
Friday, approximately 24 h after the last allergen/placebo 
dose. The methacholine challenge test was always started at 
a concentration of 0.03 mg ml - ‘, and then continued with 
two-fold increasing concentrations every fifth minute, with 
one FEV, manoeuvre 90 and 180 s after inhalation. The 
best FEV, after each concentration was used for calcula- 
tions. When FEV, had fallen with at least 20%, the 
provocation test was stopped. On Mondays, the 
methacholine-induced change in FEV, was allowed to 
resolve spontaneously (within 30-60 min), before the low 
dose allergen/vehicle was given. On Fridays, the 
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methacholine-induced change in FEV, was reversed with 
inhaled beta-2 agonist (0.8 mg) salbutamol via Diskhaler). 
The logarithmic methacholine doses were plotted against 
the fall in FEV, and the methacholine PD20 was calculated 
by linear interpolation on the log-linear curve. 
Home Spivornetvy 
Ambulatory FEV, was measured five times (every 2 h), 
after leaving the clinic during the low-dose allergen/placebo 
days (Monday-Thursday), using a light weight mini flow 
turbine spirometer (Spirobank, Medical International 
Research, MIR, Roma, Italy). The spirometer alarm was 
set to go off every second hour, to make sure that the 
patients performed the manoeuvres. Furthermore, the time 
for each measurement was saved automatically by the 
spirometer. The variability in lung function was calculated 
as the best recorded ambulatory FEV, during the week, 
minus the second lowest ambulatory FEV, during the 
week, divided by the best FEV,. The second lowest FEV, 
was used to avoid variability of data due to technically 
inappropriate recordings. 
INFLAMMATORY PARAMETERS 
EosinophildECP 
Samples for blood differential counts were taken every day, 
prior to allergen/placebo inhalation, and were subsequently 
analysed using a hospital standardised method. Samples for 
ECP-qualification were taken on Monday, Wednesday 
(before allergen), and on Friday, approximately 24 h after 
the last allergen/vehicle dose. ECP was measured with a 
fluoroimmunoassay method (Pharmacia ECP CAP System 
FEIA, Pharmacia Diagnostics AB, Uppsala, Sweden) and 
handled according to the manufacturer’s instruction. 
FACS-analysis 
Sub-populations of lymphocytes in peripheral blood were 
determined by flow cytometry. The samples were stained 
with combinations of murine monoclonal antibodies, 
directly conjugated with fluorochromes. Fluorescein 
isothiocyanate-conjugated CD4 and CD8, phycoerythrin- 
conjugated CD25 and Per-CP-conjugated CD3 and CD 19 
(Becton-Dickinson Inc., Mountain View, CA, USA) were 
used. One ml of whole EDTA-blood was treated with 10 ml 
of lysing solution (Ortho Diagnostic Systems Inc., Raritan, 
NJ, U.S.A.) and incubated for 10 min at room temperature. 
After washing once the cell concentration was adjusted to 
4 x lo6 ml - ’ and 25 bl- ’ was incubated with 10 ~1 of each 
monoclonal antibody for 15 min at room temperature. 
After washing twice, the cells were fixed in 1% paraformal- 
dehyde in phosphate buffered saline (PBS) for 10 min in 
room temperature. The cells were stored at 4°C and were 
analysed the next day on a FACScan flow cytometer 
(Becton- Dickinson Inc.), calibrated with CALIBRETTEG 
beads (Becton-Dickinson Inc.) and AutoCOMPO soft- 
ware (Becton-Dickinson Inc.). A lymphocyte gate was set 
FIG. 2. Mean change in FEV, at the screening day, in the 
eight analysed patients with early and late reactions. 
manually according to the location in the forward scatter 
versus side scatter diagram. Negative isotype controls 
(Becton-Dickinson Inc.) were used to set quadrant markers 
which delineated positive fluorescent staining from non- 
antigen specific staining. Dot plots and quadrant statistics 
from three-colour analysis were generated by the CellQuest 
software (Becton-Dickinson Inc.). The absolute number of 
blood lymphocytes was determined using a haematological 
cell counter (Sysmex-K 1000; TOA Medical Electronics 
Co). 
STATISTICS 
The change in PD20 methacholine from Monday to 
Friday during allergen/placebo exposure weeks were 
decided to be the primary end-point in the present study. 
Secondary end-points are variability in lung function (home 
spirometry), recorded number of occasions with asthma 
symptoms, use of beta-2 agonist, change in peripheral 
blood eosinophils, change in P-ECP, and change in 
circulating inflammatory cell surface markers using FACS- 
analysis. A two-tailed Student’s t-test for paired observa- 
tions was used to determine significance. A P value co.05 is 
considered significant. The results are presented as mean 
values * SEM. 
Results 
One of the nine randomised patients experienced several 
accidental and symptomatic cat exposures during the study, 
and was therefore excluded, leaving eight patients for 
analysis (Table 1). The mean per cent changes in FEV, at 
different time points during the high-dose allergen screening 
day are shown in Fig. 2. The induced EAR caused a 
mean maximal drop in FEV, of 29 f 2%, and the LAR 
21 It 2%. 
METHACHOLINE REACTIVITY 
The mean baseline methacholine PD20 was slightly higher 
before the repeated low-dose allergen week compared to 
before the placebo week (46.6 + 1.81 and 27.9 i 1.84pg 
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FIG. 3. Change in PD20 methacholine during the 
repeated low dose allergen exposure week and the placebo 
week (-, individualised low dose allergen; - - -, 
placebo). The change in PD20 methacholine from 
Monday to Friday was found to be statistically significant 
(P=O.O46). 
respectively). On the Friday after the repeated low-dose 
allergen week, the sensitivity to methacholine was increased 
compared with the placebo week (mean PD20 25.2 % 1.7 
and 59.5 + 1.7pg respectively), the change from the 
Monday being statistically significant between the two 
weeks (Fig. 3; P=O.O46). 
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LUNG FUNCTION AND SYMPTOMS Time (min) 
No significant changes in baseline FEV, was found during 
the repeated low-dose allergen week vs. the placebo week 
[Fig. 4(a)]. The individual low dose allergen challenges 
caused small immediate decreases in FEV, [Fig. 4(bbe)] 
which were found to be significant vs. respective placebo 
exposure mainly on the second study day [Tuesday; 
Fig. 4(c)]. Ambulatory spirometry showed increased vari- 
ability in lung function during the repeated low-dose 
allergen week vs. the placebo week [Fig. 5(a,b)], which also 
was associated with significantly increased number of epi- 
sodes of asthma symptoms [Fig. 5(c)], but not significantly 
increased use of beta-2 agonists [Fig. 5(e)]. Six of eight 
patients reported episodes of asthma symptoms at least 
once during the repeated low-dose allergen week, and one 
patient reported asthma symptoms once during the placebo 
week. 
FIG. 4. (a) Baseline morning FEV, prior to allergen 
exposure during the placebo and individualised low dose 
allergen exposure weeks (-- , individualised low dose 
allergen; - ~ -, placebo). (b-e) Mean per cent change in 
FEV, up to 1 h after the inhalation of placebo or 
individualised low dose allergen exposure on Monday to 
Thursday respectively (- , individualised low dose 
allergen; p-p1 placebo). Significant drop in FEV, was 
found mainly on Tuesday (P~0.05). 
and changes in methacholine reactivity was found (data 
not shown). 
We found no significant changes in circulating inflamma- 
tory T-cell or B- cell surface markers during the repeated 
low-dose allergen week vs. the placebo week, evaluated by 
FACS (Table 2). 
INFLAMMATORY PARAMETERS 
Baseline eosinophils and ECP were not significantly 
different prior to the repeated low-dose allergen and 
placebo weeks (P-ECP; 17 f 3 and 21 * 5pg 1~ r before 
the low dose allergen and placebo weeks respectively). 
No significant changes in circulating eosinophils were 
found during the repeated low-dose allergen week vs. the 
placebo week [Fig. 6(a)]. However, P- ECP increased 
slightly but statistically significant during the repeated 
low-dose allergen week vs. the placebo week [Fig. 6(b)]. 
No significant correlation between the change in P-ECP 
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Discussion 
The present double blind and placebo controlled study 
shows that repeated individualised low doses of allergen 
produces increased bronchial reactivity, increased vari- 
ability in lung function, increased asthma symptoms and 
discrete increases in ECP, suggesting that a mild asthmatic 
exacerbation was induced. 
When planning this study, we decided to monitor metha- 
choline reactivity, asthma symptoms, the use of beta-2 
agonists, as well as daily variability in lung function, 
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FIG. 5. (a) Mean afternoon variability in FEV’ Monday 
to Thursday during repeated low dose allergen week vs. 
the placebo week (- individualised low dose allergen; 
- -, placebo). (b) Mean maximal variability in FEV, 
during the repeated low dose allergen week vs. the 
placebo week (- repeated low dose allergen; - - -, 
placebo). The maximal variability in ambulatory FEV, 
was significantly higher during the low dose allergen 
week (PcO.05). (c) Mean number of periods of asthma 
symptoms during the repeated low dose allergen week vs. 
the placebo week (- individualised low dose allergen; 
- -, placebo). Significantly higher number of periods of 
symptoms were induced during the low dose allergen 
week (P~0.01). (d) Mean number of occasions of use of 
beta-2 agonist during the repeated low dose allergen 
week vs. the placebo week (- , individualised low dose 
allergen; - - -, placebo). 
because increases in these variables would be signs of an 
exacerbations of asthma (13,29-31). The repeated indi- 
vidualised low doses of allergen induced a mean increase in 
bronchial reactivity to methacholine by approximately one 
doubling dose, and this increase in reactivity was paralleled 
by a small increase in the number of occasions of asthma 
symptoms over the 4-day exposure period, but only a 
non-significant tendency towards an increased use of beta-2 
agonists. Worsening of asthma was however further con- 
firmed by increased variability of lung function, measured 
by ambulatory spirometry every other hour during the 
study weeks. Thus, of these four clinical parameters, three 
statistically supported the hypothesis that the low-dose 
allergen exposure protocol would cause an exacerbation of 
asthma. Importantly, baseline lung function, prior to each 
low-dose allergen exposure, did not significantly deteriorate 
during the study week. Thus, no overt or prolonged airflow 
obstruction was induced by the low doses of allergen, and 
Mon Tues Wed Thurs Fri 
(b) * 
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FIG. 6. (a) Mean change in blood eosinophil number 
during the repeated low dose allergen week vs. the 
placebo week (-, individualised low dose allergen; 
- -: placebo). There was no statistically significant 
difference between the two weeks. (b) Mean change in 
P-ECP during the repeated low dose allergen week vs. the 
placebo week (-- individualised low dose allergen; 
-- placebo). The’increase of P-ECP amounted to 
approximately 10,~g vs. placebo on the Friday, which is 
statistically significant (PcO.05). 
the induced changes in bronchial hyperreactivity, symp- 
toms and variability of lung function were quite small, 
suggesting that the induced exacerbations are mild. 
Asthma has been strongly associated with ongoing eosi- 
nophilic inflammation in the airways, illustrated by 
increased circulatory eosinophils, increased P-ECP and 
increased number of eosinophils in the airway wall and 
sputum (9-12,32). In the present study, we found that the 
low-dose allergen exposure slightly increased the level of 
P-ECP, although the number of circulating eosinophils 
were not significantly increased, further supporting that a 
mild exacerbation of asthma was induced. No increase in 
P-ECP was found in a previous study of low-dose allergen 
exposure (25) but in that case, the dose of allergen was not 
chosen on the basis of the patients own allergen-reactivity. 
In another study, in which the investigators gave low doses 
of allergen intranasally to patients with allergic rhinitis, 
ECP was found to be increased in nasal lavage, but not in 
the circulation, suggesting that the local inflammatory 
response may be stronger than implied in the P-ECP (28). 
This is further supported by a recent preliminary report, 
showing that repeated low-doses of allergen increases the 
relative amount of eosinophils in induced sputum (33). 
The observed sign of discrete activation of circulatory 
eosinophils in the present study, was not paralleled by an 
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TABLE 2. Effects of repeated low dose allergen exposure on the total number of peripheral blod 
lymphocytes (X 106 per ml), measured by FACS analysis on Monday prior to allergen, and on 
Wednesday and Friday 24 h after the latest low dose allergen exposure (data shown as mean). The 
statistics are performed on the changed of total number of respective lymphocyte subset during the 
placebo and allergen weeks respectively (Delta) 
Mon 
Placebo week Allergen week 
Wed Fri Delta Mon Wed Fri Delta P= 
CD3 1.33 1.23 1.4 0.07 1.2 1.22 1.23 0.03 0.86 
CD3+4 0.68 0.65 0.79 0.11 0.62 0.61 0.66 0.04 0.71 
CD3+8 0.23 0.32 0.33 0.10 0.24 0.25 0.31 0.07 0.72 
CD4/CD8 3.78 2.31 2.61 - 1.17 4.41 4.00 3.54 - 0.87 0.94 
CD3+4+25 0.28 0.34 2.61 0.08 0.28 0.29 0.26 - 0.02 0.30 
CD3+8+25 0.02 0.02 0.02 0.02 0.02 0.02 0.06 0.04 0.61 
CD19 0.12 0.12 0.01 0.01 0.10 0.08 0.08 - 0.02 0.77 
increase of the analysed sub-populations of CD3, CD4, 
CD8, CD19 and CD25 lymphocytes in peripheral blood. 
This would imply that lymphocytes were not activated by 
the low-dose allergen exposure, at least not to a degree 
being reflected in the circulation. 
This study has not in a randomised way compared the 
effects of repeated low-dose allergen exposure with a a 
single high dose challenge. However, our data in relation to 
the previous studies, imply that the degree of change of 
bronchial reactivity is quite similar in the two models 
(18,21). Furthermore, giving repeated low doses of allergen 
seems to be quite safe, because no or very small changes in 
lung function are induced with the low-dose protocol 
compared to the screening day, and the number of 
occasions with asthma symptoms are rare. Future 
studies, directly comparing the effects of a single high dose 
challenge with those of repeated low doses of allergen, will 
give us further insight into the differences and similarities 
of these two different ways of giving experimental 
allergen-challenge to allergic asthmatic patients. 
The combination of data in this study, showing parallel 
increases in P-ECP, BHR, variability of FEV, and 
increased number of asthma symptoms during the low-dose 
allergen week, confirm that these parameters may be closely 
linked in asthma. Thus, it is possible, as has been proposed 
(3,4,10), that the activation of eosinophils is important for 
the increase in methacholine reactivity and increased vari- 
ability of lung function, which in turn results in increased 
number of periods of asthma symptoms. It seems unlikely 
that the increased methacholine reactivity observed after 
repeated low-dose allergen exposure is independent of 
eosinophilic inflammation, as was implied previously (25). 
This study suggests that repeated and individualised low 
dose exposure to allergen causes several features of an 
exacerbation of asthma in sensitive individuals, reflected in 
increased methacholine reactivity, increased symptoms of 
asthma, increased variability of lung function, and a small 
increase in P-ECP. These changes were, however, small in 
magnitude, suggesting that the induced exacerbations are 
quite mild. We believe that this model may become useful in 
the clinical evaluation of novel anti-asthma drugs, as a 
complement to the more commonly used high-dose 
allergen-exposure model (1621). 
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